tbuckley/cabot-search huggingface dataset:
Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
Authors: Anne Quinquenel, Thérèse Aurran‐Schleinitz, Aline Clavert, Florence Cymbalista, Caroline Dartigeas, Frédéric Davi, Sophie de Guibert, Alain Delmer, Marie‐Sarah Dilhuydy, Pierre Feugier, Luc‐Matthieu Fornecker, David Ghez, Romain Guieze, Kamel Laribi, Véronique Leblond, Stéphane Leprêtre, Rémi Letestu, Vincent Lévy, Florence Nguyen‐Khac, Anne‐Sophie Michallet, Cécile Tomowiak, Olivier Tournilhac, Loïc Ysebaert, Xavier Troussard
Journal: HemaSphere (2020)

Abstract As a result of significant recent developments, the management of patients with chronic lymphocytic leukemia (CLL) is changing, and new therapeutic options will continue to emerge in the near future. The recommendations of the French Innovative Leukemia Organization (FILO‐CLL) group presented here are intended to provide practical recommendations for physicians taking care of CLL patients, taking into account the availability of both biological tests and therapies in daily practice in France at the time of publication. This text details the documented information and guidelines on diagnosis, indications for treatment, infectious complications and therapeutic strategies in frontline and relapsed CLL as well as in particular conditions such as autoimmune cytopenia or Richter syndrome.
649P Abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy: A double-arm, multiple-centre, phase III clinical study
Authors: Z. Hu, Z. Ye, H. Zeng, Y. Huang, D. Ye, B. Shi, H. Luo, C. Du, W. An, L. Zhou, L. Hua, T. Pan, C. He, F. Zhou, J. Li, Y. Deng, Y. Bai, H. Li
Journal: Annals of Oncology (2020)
Covid-19: Risk of death more than doubled in people who also had flu, English data show
Authors: Gareth Iacobucci
Journal: BMJ (2020)

Covid-19: Risk of death more than doubled in people who also had flu, English data show Gareth IacobucciPeople infected with both flu and SARS-CoV-2 are more than twice as likely to die as someone with the new coronavirus alone, emerging evidence from England has shown.
473P PLK1 expression and KRAS mutations in colorectal cancer
Authors: P. Jayachandran, A. Elliott, F. Battaglin, E. Lou, W. Zhang, S. Soni, H. Arai, J. Wang, J. Millstein, A.C. Lockhart, W.M. Korn, H.J. Lenz
Journal: Annals of Oncology (2020)
Prophylactic <i>Faecalibacterium prausnitzii</i> treatment prevents the acute breakdown of colonic epithelial barrier in a preclinical model of pelvic radiation disease
Authors: Alexia Lapiere, Mallia Geiger, Véronique Robert, Christelle Demarquay, Sandrine Auger, Sead Chadi, Mohamedamine Benadjaoud, Gabriel Fernandes, Fabien Milliat, Philippe Langella, Marc Benderitter, Jean-Marc Chatel, Alexandra Sémont
Journal: Gut Microbes (2020)

Every year, millions of people around the world benefit from radiation therapy to treat cancers localized in the pelvic area. Damage to healthy tissue in the radiation field can cause undesirable toxic effects leading to gastrointestinal complications called pelvic radiation disease. A change in the composition and/or function of the microbiota could contribute to radiation-induced gastrointestinal toxicity. In this study, we tested the prophylactic effect of a new generation of probiotic like Faecalibacterium prausnitzii (F. prausnitzii) on acute radiation-induced colonic lesions. Experiments were carried out in a preclinical model of pelvic radiation disease. Rats were locally irradiated at 29 Gray in the colon resulting in colonic epithelial barrier rupture. Three days before the irradiation and up to 3 d after the irradiation, the F. prausnitzii A2-165 strain was administered daily (intragastrically) to test its putative protective effects. Results showed that prophylactic F. prausnitzii treatment limits radiation-induced para-cellular hyperpermeability, as well as the infiltration of neutrophils (MPO+ cells) in the colonic mucosa. Moreover, F. prausnitzii treatment reduced the severity of the morphological change of crypts, but also preserved the pool of Sox-9+ stem/progenitor cells, the proliferating epithelial PCNA+ crypt cells and the Dclk1+/IL-25+ differentiated epithelial tuft cells. The benefit of F. prausnitzii was associated with increased production of IL-18 by colonic crypt epithelial cells. Thus, F. prausnitzii treatment protected the epithelial colonic barrier from colorectal irradiation. New-generation probiotics may be promising prophylactic treatments to reduce acute side effects in patients treated with radiation therapy and may improve their quality of life.
107P Immune Checkpoint Inhibitor (ICPI) resistance genes STK11 and KEAP1: A comparative Comprehensive Genomic Profiling (CGP) study
Authors: B. Alexander, E.S. Sokol, N.A. Danziger, D.C. Pavlick, J. Elvin, J.K. Killian, D.I. Lin, E. Williams, S. Ramkissoon, E. Severson, A. Hemmerich, D. Duncan, C. Edgerly, R. Huang, M. Hiemenz, P. Reddy, K. McGregor, J. Venstrom, A.B. Schrock, J.S. Ross
Journal: Annals of Oncology (2020)
324P What affects the choice of first-line treatment for hormone-receptor-positive, HER2-negative advanced breast cancer? Data from the German research platform OPAL
Authors: A. Welt, M. Thill, E. Stickeler, M-O. Zahn, A. Nusch, M. Zaiss, U. Neef, S. Fruehauf, R. Buss-Steidle, V. Hagen, M. Chiabudini, L. Kruggel, M. Jänicke, N.W. Marschner, A. Wöckel, N. Harbeck, T. Decker
Journal: Annals of Oncology (2020)
1860P Results and feasibility of a realistic designed geriatric assessment (RDGA) in an outpatient Brazilian Oncology unit
Authors: A.F. Ferreira Filho, D.S.L. Daniela, S.L. Juliana, B.F. Caroline, B.S. Estela, D.O.K. Vanessa, D.H. Rosimeri
Journal: Annals of Oncology (2020)
285P Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis
Authors: F. Marazzi, A. Orlandi, V. Masiello, T. Zinicola, F. Moschella, S. Chiesa, V. Frascino, G. Franceschini, E. Bria, M.A. Gambacorta, R. Masetti, C. Aristei, G. Tortora, V. Valentini
Journal: Annals of Oncology (2020)
524O Initial results of a phase I study of MK-4830, a first-in-class anti–immunoglobulin-like transcript 4 (ILT4) myeloid-specific antibody in patients (pts) with advanced solid tumours
Authors: L.L. Siu, D. Wang, J. Hilton, R. Geva, D. Rasco, A.K. Abraham, J.F. Markensohn, L. Suttner, S. Siddiqi, R.A. Altura, C. Maurice-Dror
Journal: Annals of Oncology (2020)
69P PD-L1 expression as a prognostic marker in patients with advanced biliary tract cancer
Authors: H. Kim, J. Kim, S. Byeon, J.Y. Hong, J. Lee, S.H. Park, J.O. Park, Y.S. Park, H.Y. Lim, W.K. Kang, S.T. Kim
Journal: Annals of Oncology (2020)
LBA26 Phase II study of the oral HIF-2α inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC): Update on RCC and non-RCC disease
Authors: R. Srinivasan, F. Donskov, O. Iliopoulos, W.K. Rathmell, V.K. Narayan, B.L. Maughan, S. Oudard, T. Else, J.K. Maranchie, S.J. Welsh, S. Thamake, E.K. Park, R.F. Perini, W.M. Linehan, E. Jonasch
Journal: Annals of Oncology (2020)
1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
Authors: L.S. Wyrwicz, K-W. Lee, E. Van Cutsem, Y-J. Bang, C.S. Fuchs, I. Kudaba, M. Garrido, H.C. Chung, J. Lee, H.R. Castro, J. Chao, Z.A. Wainberg, Z.A. Cao, D. Aurora-Garg, J. Kobie, R. Cristescu, P. Bhagia, S. Shah, J. Tabernero, K. Shitara
Journal: Annals of Oncology (2020)
313P Real-world multi-country study of treatment trends among patients (pts) with HER2− BRCA1/2 mutated (BRCA1/2mut) advanced breast cancer (ABC)
Authors: R. Mahtani, A. Niyazov, K. Lewis, L. Massey, A. Rider, B. Arondekar, M.P. Lux
Journal: Annals of Oncology (2020)
<i>AACR Cancer Progress</i> <i>Report 2020</i>: Turning Science into Lifesaving Care
Authors: Rajarshi Sengupta, Karen Honey
Journal: Clinical Cancer Research (2020)

The American Association for Cancer Research (AACR) is proud to announce the release of the AACR Cancer Progress Report 2020 . This 10th edition of the annual report details how research is the backbone of progress across the spectrum of lifesaving cancer care. The full report, and all nine prior
492P A multicenter LArge retrospectIve daTabase on the personalization of Stereotactic ABlative Radiotherapy for lung metastases from colorectal cancer: Early results from the LaIT-SABR study
Authors: L. Nicosia, M. Rigo, D. Franceschini, M. Scorsetti, F. Perrone Congedi, M.F. Osti, A. Ravasio, V. Vavassori, P. Borghetti, S.M. Magrini, A. Bruni, L. Frassinelli, F. Lohr, A. Di Marzo, E. Maranzano, B. De Bari, R. Mazzola, F. Alongi
Journal: Annals of Oncology (2020)
427P Value of magnetic resonance diffusion weighted imaging in the identification of complete responder patients with rectal cancer treated with neoadjuvant therapy
Authors: J-R. Ayuso, C. Pérez-Serrano, M. Pagés, S. Rodríguez-Gómez, T.D. Barreto Zambrano, C. Conill, J. Maurel
Journal: Annals of Oncology (2020)
ZnO-based multifunctional nanocomposites to inhibit progression and metastasis of melanoma by eliciting antitumor immunity via immunogenic cell death
Authors: Yamin Zhang, Chen Guo, Liping Liu, Jian Xu, Hao Jiang, Danqi Li, Jiajia Lan, Jun Li, Jing Yang, Qiming Tu, Xiaoyan Sun, Mahin Alamgir, Xiang Chen, Guanxin Shen, Jintao Zhu, Juan Tao
Journal: Theranostics (2020)

Rationale: The development of a highly effective and tumor-specific therapeutic strategy, which can act against the primary tumor and also condition the host immune system to eliminate distant tumors, remains a clinical challenge. Methods: Herein, we demonstrate a facile yet versatile ZnO-capping and Doxorubicin (DOX)-loaded multifunctional nanocomposite (AuNP@mSiO2@DOX-ZnO) that integrates photothermal properties of gold nanoparticles (NPs), pH-responsive properties and preferential selectivity to tumor cells of ZnO QDs and chemotherapeutic agent into a single NP. The photothermal performance, pH-triggered release and preferential phagocytic ability were assessed. The induced anti-tumor immunity was determined by analyzing immune cell profile in tumor in vivo and molecular mechanism were identified by detecting expression of immunogenic cell death (ICD) markers in vitro. Moreover, mice models of unilateral and bilateral subcutaneous melanoma and lung metastasis were established to evaluate the antitumor effects. Results: As an efficient drug carrier, ZnO-capped NPs guarantee a high DOX payload and an in vitro, efficient release of at pH 5.0. In murine melanoma models, the nanocomposite can significantly inhibit tumor growth for a short period upon low-power laser irradiation. Importantly, ZnO NPs not only demonstrate preferential selectivity for melanoma cells but can also induce ICD. Meanwhile, AuNP@mSiO2-based photothermal therapy (PTT) and DOX are directly cytotoxic towards cancer cells and demonstrate an elevated ICD effect. The induced ICD promotes maturation of dendritic cells, further stimulating the infiltration of effector T cells into tumor sites, preventing tumor growth and distant lung metastases. Conclusions: This study highlights the novel mechanism of ZnO-triggered anti-tumor immunity via inducing ICD. Additionally, we shed light on the multifunctionality of nanocomposites in delivering localized skin tumor therapy as well as inhibiting metastatic growth, which holds great promise in clinical applications.
1183P Sequential PRRT and SIRT: Evaluation of safety, toxicity and best sequence treatment in liver dominant GEPNETs
Authors: F. Scalorbi, A. Lorenzoni, S. Mazzaglia, E. Garanzini, C. Chiesa, G. Aliberti, G. Argiroffi, S. Pusceddu, N. Prinzi, C. Spreafico, G. Centonze, J. Coppa, A. Marchianò, M. Milione, V. Mazzaferro, E. Seregni, M. Maccauro
Journal: Annals of Oncology (2020)
1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical resection or local ablation
Authors: A. Vogel, A.X. Zhu, A-L. Cheng, T. Yau, J. Zhou, E. Kim, U. Malhotra, A.B. Siegel, M. Kudo
Journal: Annals of Oncology (2020)
1862P Geriatric assessment tools and preliminary patient-reported outcomes in a cohort of elderly patients treated with 1.5T MR guided abdominal-pelvic SBRT
Authors: R. Mazzola, V. Figlia, M. Rigo, F. Cuccia, F. Ricchetti, N. Giaj-Levra, L. Nicosia, C. Vitale, G. Sicignano, A. De Simone, S. Naccarato, R. Ruggieri, F. Alongi
Journal: Annals of Oncology (2020)
1968P The clinical effect of concurrent oncogenic gene mutations in BRAF p.(V600E)-mutated NSCLC treated with dabrafenib and trametinib
Authors: P. Meng, B. Koopman, K. Kok, A. ter Elst, E. Schuuring, L.C. van Kempen, W. Timens, T.J.N. Hiltermann, H.J.M. Groen, A. van den Berg, A.J. van der Wekken
Journal: Annals of Oncology (2020)
Incidence, Characteristics, and Outcomes of Interval Breast Cancers Compared With Screening-Detected Breast Cancers
Authors: Saroj Niraula, Natalie Biswanger, PingZhao Hu, Pascal Lambert, Kathleen Decker
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Breast cancer comprises a highly heterogeneous group of diseases. Many breast cancers, particularly the more lethal ones, may not satisfy the assumptions about biology and natural history of breast cancer necessary for screening mammography to be effective. <h3>Objectives</h3> To compare tumor characteristics of breast cancers diagnosed within 2 years of a normal screening mammogram (interval breast cancer [IBC]) with those of screen-detected breast cancers (SBC) and to compare breast cancer–specific mortality of IBC with SBC. <h3>Design, Setting, and Participants</h3> In this registry-based cohort study, we collected data about relevant tumor- and patient-related variables on women diagnosed with breast cancer between January 2004 and June 2010 who participated in the population-based screening program in Manitoba, Canada, and those diagnosed with breast cancer outside the screening program in the province. We performed multinomial logistic regression analysis to assess tumor and patient characteristics associated with a diagnosis of IBC compared with SBC. Competing risk analysis was performed to examine risk of death by cancer detection method. <h3>Exposures</h3> Breast cancer diagnosis. <h3>Main Outcomes and Measures</h3> Differences in tumor characteristics and breast cancer–specific mortality. <h3>Results</h3> A total of 69 025 women aged 50 to 64 years had 212 579 screening mammograms during the study period. There were 1687 breast cancer diagnoses (705 SBC, 206 IBC, 275 were noncompliant, and 501 were detected outside the screening program), and 225 deaths (170 breast cancer–specific deaths). Interval cancers were more likely than SBC to be of high grade and estrogen receptor negative (odds ratio [OR], 6.33; 95% CI, 3.73-10.75;<i>P</i> &lt; .001; and OR, 2.88; 95% CI, 2.01-4.13;<i>P</i> &lt; .001, respectively). After a median follow-up of 7 years, breast cancer–specific mortality was significantly higher for IBC compared with SBC cancers (hazard ratio [HR] 3.55; 95% CI, 2.01-6.28;<i>P</i> &lt; .001), for a sojorn time of 2 years. Non–breast cancer mortality was similar between IBC and SBC (HR, 1.33; 95% CI, 0.43-4.15). <h3>Conclusions and Relevance</h3> In this cohort study, interval cancers were highly prevalent in women participating in population screening, represented a worse biology, and had a hazard for breast cancer death more than 3-fold that for SBC. Strategies beyond current mammographic screening practices are needed to reduce incidence, improve detection, and reduce deaths from these potentially lethal breast cancers.
1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing
Authors: B. Markman, D. Day, J.J.W. Park, J. Coward, S. Bishnoi, D. Kotasek, R. Eek, M.P. Brown, C. Lemech, J. Kuo, A. Prawira, R. Strother, Q. Zhang, L. Wang, R. Chen, Y. Ma, Z. Qin, A. Tse
Journal: Annals of Oncology (2020)
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies
Authors: Valentín Ortíz-Maldonado, Susana Rives, Maria Castellà, Anna Alonso-Saladrigues, Daniel Benítez-Ribas, Miguel Caballero-Baños, Tycho Baumann, Joan Cid, Enric Garcia-Rey, Cristina Llanos, Montserrat Torrebadell, Neus Villamor, Eva Giné, Marina Díaz-Beyá, Laia Guardia, Mercedes Montoro, Albert Català, Anna Faura, E. Azucena González, Marta Español-Rego, Nela Klein-González, Laia Alsina, Pedro Castro, Iolanda Jordan, Sara Fernández, Federico Ramos, Guillermo Suñé, Unai Perpiñá, Josep M. Canals, Miquel Lozano, Esteve Trias, Andrea Scalise, Sara Varea, Joaquín Sáez-Peñataro, Ferran Torres, Gonzalo Calvo, Jordi Esteve, Álvaro Urbano-Ispizua, Manel Juan, Julio Delgado
Journal: Molecular Therapy (2020)

We evaluated the administration of ARI-0001 cells (chimeric antigen receptor T cells targeting CD19) in adult and pediatric patients with relapsed/refractory CD19+ malignancies. Patients received cyclophosphamide and fludarabine followed by ARI-0001 cells at a dose of 0.4-5 × 106 ARI-0001 cells/kg, initially as a single dose and later split into 3 fractions (10%, 30%, and 60%) with full administration depending on the absence of cytokine release syndrome (CRS). 58 patients were included, of which 47 received therapy: 38 with acute lymphoblastic leukemia (ALL), 8 with non-Hodgkin's lymphoma, and 1 with chronic lymphocytic leukemia. In patients with ALL, grade ≥3 CRS was observed in 13.2% (26.7% before versus 4.3% after the amendment), grade ≥3 neurotoxicity was observed in 2.6%, and the procedure-related mortality was 7.9% at day +100, with no procedure-related deaths after the amendment. The measurable residual disease-negative complete response rate was 71.1% at day +100. Progression-free survival was 47% (95% IC 27%-67%) at 1 year: 51.3% before versus 39.5% after the amendment. Overall survival was 68.6% (95% IC 49.2%-88%) at 1 year. In conclusion, the administration of ARI-0001 cells provided safety and efficacy results that are comparable with other academic or commercially available products. This trial was registered as ClinicalTrials.gov: NCT03144583.
909P Efficacy and safety of HHPG-19K for prophylaxis of chemotherapy-induced neutropenia in patients with lymphoma
Authors: M. Zheng, J. Zhao, L. Ma, X. Wen, J. Wang, S. Wu, Y. Wang, M. Bai, Z. Zhao, H. Zhang, B. Yang, Y. Zheng, W. Han, L. Wang, L. Su
Journal: Annals of Oncology (2020)
457P 1st-line panitumumab plus FOLFIRI or FOLFOX for patients with RAS wildtype metastatic colorectal cancer in Germany: Interim results of the non-interventional study VALIDATE
Authors: J. Uhlig, J. Potenberg, D. Semsek, P. Stübs, C.D. Fichter, A. Köhler, L. Müller, M. Reiser, H.U. Siebenbach, T. Göhler, L. Jacobasch, V. Kächele, B. Timm, K. Potthoff, N.W. Marschner
Journal: Annals of Oncology (2020)
1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy
Authors: S. Merler, S. Zuliani, I. Zampiva, D. Tregnago, M. Casali, A. Cavaliere, A. Fumagalli, S.T. Riva, A. Rossi, F. Zacchi, E. Zaninotto, A. Auriemma, M. Pavarana, C. Soldà, L. Benini, M. Borghesani, G. Lo Cascio, E. Tacconelli, S. Pilotto, M. Milella
Journal: Annals of Oncology (2020)
503P The Screening and COnsensus based on Practices and Evidence (SCOPE) survey: Treatment goals and practice patterns in third- and fourth-line metastatic colorectal cancer
Authors: G. Prager, C-H. Kohne, J.M. O'Connor, F. Rivera, D. Santini, H. Wasan, J.M. Phelip
Journal: Annals of Oncology (2020)
Effect of Neutropenic Critical Illness on Development and Prognosis of Acute Respiratory Distress Syndrome
Authors: David R. Price, Katherine L. Hoffman, Clara Oromendia, Lisa K. Torres, Edward J. Schenck, Mary E. Choi, Augustine M. K. Choi, Rebecca M. Baron, Jin-Won Huh, Ilias I. Siempos
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) Classifier
Authors: Patrick D. McGillivray, Daiki Ueno, Aydin Pooli, Neil Mendhiratta, Jamil S. Syed, Kevin A. Nguyen, Peter G. Schulam, Peter A. Humphrey, Adebowale J. Adeniran, Paul C. Boutros, Brian Shuch
Journal: European Urology (2020)
1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)
Authors: J. Capdevila, A. Teule, C. López, R. García-Carbonero, M. Benavent, A. Custodio, A. Cubillo, V. Alonso, T. Alonso Gordoa, A. Carmona-Bayonas, G. Crespo, M. Blanco-Codesido, P. Jimenez-Fonseca, A. Viúdez, A. La Casta Muñoa, I. Sevilla, M. Llanos, A. Segura, J. Hernando-Cubero, J.L. Manzano
Journal: Annals of Oncology (2020)
Mental health management of elite athletes during COVID-19: a narrative review and recommendations
Authors: Claudia L Reardon, Abhinav Bindra, Cheri Blauwet, Richard Budgett, Niccolo Campriani, Alan Currie, Vincent Gouttebarge, David McDuff, Margo Mountjoy, Rosemary Purcell, Margot Putukian, Simon Rice, Brian Hainline
Journal: British Journal of Sports Medicine (2020)

Elite athletes suffer many mental health symptoms and disorders at rates equivalent to or exceeding those of the general population. COVID-19 has created new strains on elite athletes, thus potentially increasing their vulnerability to mental health symptoms. This manuscript serves as a narrative review of the impact of the pandemic on management of those symptoms in elite athletes and ensuing recommendations to guide that management. It specifically addresses psychotherapy, pharmacotherapy and higher levels of care. Within the realm of psychotherapy, crisis counselling might be indicated. Individual, couple/family and group psychotherapy modalities all may be helpful during the pandemic, with novel content and means of delivery. Regarding pharmacotherapy for mental health symptoms and disorders, some important aspects of management have changed during the pandemic, particularly for certain classes of medication including stimulants, medications for bipolar and psychotic disorders, antidepressants and medications for substance use disorders. Providers must consider when in-person management (eg, for physical examination, laboratory testing) or higher levels of care (eg, for crisis stabilisation) is necessary, despite potential risk of viral exposure during the pandemic. Management ultimately should continue to follow general principles of quality health care with some flexibility. Finally, the current pandemic provides an important opportunity for research on new methods of providing mental health care for athletes, and consideration for whether these new methods should extend beyond the pandemic.
1046P Outcomes of patients with solid tumour malignancies treated with first-line (1L) immuno-oncology (IO) agents who do not meet eligibility criteria for clinical trials
Authors: C.L. Gan, I. Stukalin, D.E. Meyers, S. Dudani, H.A.I. Grosjean, S. Dolter, B.W. Ewanchuk, S. Goutam, M. Sander, J.C. Wells, A. Pabani, T. Cheng, J. Monzon, D. Morris, N.S. Basappa, S.K. Pal, L.A. Wood, F. Donskov, T.K. Choueiri, D.Y.C. Heng
Journal: Annals of Oncology (2020)
65P Prognostic role of PECS2 index in advanced biliary tract cancer (BTC) patients treated with first line chemotherapy: Training and validation cohorts
Authors: G. Rovesti, F. Leone, G. Brandi, S. Cesario, M. Scartozzi, M. Niger, C. Yoo, R. Filippi, M. Casagrande, N. Silvestris, D. Santini, L. Faloppi, M. Aglietta, H. Cho, E. Lai, F. De Braud, J.H. Jeong, G. Aprile, S. Cascinu, A. Casadei Gardini
Journal: Annals of Oncology (2020)
1702P COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study
Authors: F. Nichetti, M. Bini, K.F. Dotti, A. Ottini, M. Ambrosini, A. Rametta, R. Leporati, L. Ferrari, F.G.M. De Braud
Journal: Annals of Oncology (2020)